Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study.

Jensen RH, Schytz HW, Tassorelli C, Terwindt GM, Carlsen LN, Mittoux A, Østerberg O, Lipton RB, Tepper SJ, Blumenfeld A, Lundqvist C

Open source

DOI
10.3389/fneur.2023.1114654
Published
2023
Container
Frontiers in neurology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2023.1114654,
  title = {Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study.},
  author = {Jensen RH and Schytz HW and Tassorelli C and Terwindt GM and Carlsen LN and Mittoux A and Østerberg O and Lipton RB and Tepper SJ and Blumenfeld A and Lundqvist C},
  year = {2023},
  journal = {Frontiers in neurology},
  doi = {10.3389/fneur.2023.1114654},
  url = {https://doi.org/10.3389/fneur.2023.1114654}
}

RIS

TY  - JOUR
TI  - Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study.
AU  - Jensen RH
AU  - Schytz HW
AU  - Tassorelli C
AU  - Terwindt GM
AU  - Carlsen LN
AU  - Mittoux A
AU  - Østerberg O
AU  - Lipton RB
AU  - Tepper SJ
AU  - Blumenfeld A
AU  - Lundqvist C
PY  - 2023
JO  - Frontiers in neurology
DO  - 10.3389/fneur.2023.1114654
UR  - https://doi.org/10.3389/fneur.2023.1114654
ER  - 

APA

RH, J., HW, S., C, T., GM, T., LN, C., A, M., O, Ø., RB, L., SJ, T., A, B., & C, L. (2023). Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study.. Frontiers in neurology. https://doi.org/10.3389/fneur.2023.1114654

Source records